CaseVu
Precipio & ADS Biotec Launch Seven Beta Sites For IV-Cell™
Prominent Laboratories in US and Europe will begin testing the media NEW HAVEN, CT, (October [...]
Oct
Precipio Launches Its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
Panel of clinically critical genes can yield same-day results outperforming major competitors NEW HAVEN, CT, [...]
Sep
Precipio Announces A Shareholder Call To Discuss Its COVID-19 Progress And Future Plans
Ilan Danieli, Precipio CEO, will address questions from shareholders related to company COVID-19 strategy NEW [...]
Sep
Precipio & ADS Biotec Sign Global Distribution Agreement For IV-Cell™
Partnership is expected to accelerate product introduction to most major labs worldwide NEW HAVEN, CT, [...]
Aug
Precipio Announces Q2-2020 Corporate Update Call For Shareholders
Conference Call to be held on Monday, August 17th, 2020 at 5:00 PM EST NEW [...]
Aug
Precipio Launches Covid-19 Antibody Test In Its CLIA Laboratory
Test initially offered to Precipio’s customer base, then expanding distribution reach NEW HAVEN, CT, (August [...]
Aug
Precipio Announces Commercial Launch Of Covid-19 Antibody Test
Test received FDA EUA; commercialization begins NEW HAVEN, CT, (July 30th, 2020) – Specialty diagnostics company Precipio, [...]
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% Over Q1’20
NEW HAVEN, CT, (July 22nd, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited [...]
Jul
Precipio Regains Listing Compliance With NASDAQ Minimum Bid Requirement
NEW HAVEN, CT, (July 1st, 2020) – Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has [...]
Jul
Precipio Adds Another HemeScreen™ Customer
Newly Created Reagent Rental Program Continues to Gain HemeScreen Adopters NEW HAVEN, CT, (June 9th, [...]
Jun